CODX
Co-Diagnostics, Inc.
There isn't enough reported data to score CODX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CODX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
CODX's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CODX PE Valuation
CODX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CODX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CODX's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CODX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$22.88 | +$6.82 |
| Q2 2026 | -$26.67 | +$7.83 |
| Q1 2026 | -$32.11 | +$2.99 |
| Q4 2025 | -$35.25 | +$1.95 |
| Q3 2025 | -$29.70 | +$11.40 |
| Q2 2025 | -$34.50 | +$3.00 |
| Q1 2025 | -$35.10 | +$4.20 |
| Q4 2024 | -$37.20 | -$1.20 |
CODX is still losing money, but less than at its worst: $22.88 per share over the past year, against $41.40 at its worst in late 2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CODX on earnings quality, reporting a profit while its opponent remains loss making.
CODX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $282.9K | +95% |
| Q2 2026 | $166.1K | +2% |
| Q1 2026 | $146K | +190% |
| Q4 2025 | $263.9K | +77% |
| Q3 2025 | $145.4K | -77% |
| Q2 2025 | $162.9K | -94% |
| Q1 2025 | $50.3K | -89% |
| Q4 2024 | $149.3K | -96% |
CODX's revenue is recovering but still below its 2021 peak: $282,881 last quarter, up 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2216% | +2608 points |
| Q2 2026 | -3732% | +1214 points |
| Q1 2026 | -6309% | +10701 points |
| Q4 2025 | -10057% | -2083 points |
| Q3 2025 | -4824% | -3228 points |
| Q2 2025 | -4946% | -4657 points |
| Q1 2025 | -17010% | -14817 points |
| Q4 2024 | -7974% | -7641 points |
CODX's operating margin was −2216% last quarter, up 2608 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CODX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CODX on profitability, with a higher operating margin.
CODX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.7M | +$280.7K |
| Q2 2026 | -$7.2M | +$1.5M |
| Q1 2026 | -$8M | +$848.8K |
| Q4 2025 | -$6.3M | +$2M |
| Q3 2025 | -$6M | +$1.4M |
| Q2 2025 | -$8.7M | -$3.4M |
| Q1 2025 | -$8.8M | +$55.5K |
| Q4 2024 | -$8.3M | -$3.1M |
CODX has burned cash in most quarters: −$27M over the past year, against −$32M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CODX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CODX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +46% | +2M shares |
| 1 year | +468% | +5.2M shares |
| 3 years | +547% | +5.3M shares |
| 5 years | +533% | +5.3M shares |
| Available history | +725% | +5.5M shares |
CODX has 6M diluted shares, up 468% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $159,673 |
| Q3 2023 | $166,326 |
| Q2 2023 | $555,734 |
| Q1 2023 | $482,196 |
| Q4 2022 | $1.2M |
| Q3 2022 | $10.4M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CODX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CODX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -7.7x | Net Cash |
| Q2 2022 | -2.8x | Net Cash |
| Q1 2022 | -2.1x | Net Cash |
| Q4 2021 | -1.9x | Net Cash |
| Q3 2021 | -1.6x | Net Cash |
| Q2 2021 | -1.4x | Net Cash |
| Q1 2021 | -1.1x | Net Cash |
| Q4 2020 | -1.0x | Net Cash |
CODX has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CODX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.5 | Neutral |
| Stochastic | 0.9 | Oversold |
CODX's weekly RSI is 34 (neutral) and its Stochastic is 1 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CODX PE vs Healthcare Sector
| Metric | CODX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CODX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CODX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.67 | 60% below |
| 20 week MA | $1.28 | 79% below |
| 50 week MA | $2.84 | 90% below |
| 100 week MA | $7.77 | 97% below |
| 200 week MA | $24.5 | 99% below |
CODX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CODX on trend strength, trading above more of its moving averages.
CODX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.8 | $325.2 | +1069% |
| 2021 | $325.2 | $282.3 | -13% |
| 2022 | $282.3 | $76.5 | -73% |
| 2023 | $76.5 | $39.9 | -48% |
| 2024 | $39.9 | $21.9 | -45% |
| 2025 | $21.9 | $7.05 | -68% |
| 2026 YTD | $7.05 | $0.27 | -96% |
CODX has finished five years in a row lower, and it's down 96% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CODX on returns for 2026, with the stronger performance.